Open, uncontrolled, nonrandomized, 9-month, off-label use of bupropion to treat fatigue in a single patient with multiple sclerosis.

Abstract

BACKGROUND:

Improvement of fatigue in patients with multiple sclerosis (MS) who were given bupropion has been previously reported, but scales for lethargy and depression were not used.

OBJECTIVE:

This letter describes the course of chronic fatigue in a patient with MS who received off-label treatment with bupropion.

METHODS:

A 47-year-old white woman (weight, 56 kg) with a 7-year history of relapsing-remitting MS (Ex- panded Disability Status Scale score of 3), without previous use of medication for MS, presented with a complaint of irritability and chronic fatigue. The Fatigue Severity Scale (FSS) documented the presence of fatigue related to MS (score of 7). The Beck Depression Inventory scale excluded an association between depression and fatigue (score of 8; possible range, 0-24); both the Pittsburgh Sleep Quality Index (score of 4; possible range, 0-21) and the Epworth Sleepiness Scale (score of 6; possible range, 0-24) excluded nighttime and daytime sleep disturbances. The patient was started on amantadine (100 mg/d), with an increase to 100 mg every 12 hours 2 weeks later, for the persistence of fatigue. Three months later, the absence of clinical response was noted (FSS score of 7). Amantadine was discontinued and bupropion therapy was initiated at 300 mg/d.

RESULTS:

A repeat clinical evaluation conducted after 3 months of bupropion treatment indicated an improvement in fatigue (FSS score of 4) without changes in Beck Depression Inventory, Pittsburgh Sleep Quality Index, or Epworth Sleepiness Scale scores. The discontinuation and reinitiation of bupropion confirmed the effectiveness of bupropion for improving chronic fatigue in this patient. At the time of writing this report, 13 months after the resumption of bupropion treatment, the patient had experienced no further episodes of fatigue, and no adverse events had been reported.

CONCLUSION:

This patient with relapsing-remitting MS experienced improvements in chronic fatigue (as measured by FSS) after treatment with bupropion, but properly designed, randomized, active- and placebo-controlled clinical trials are needed to evaluate the efficacy and safety of bupropion in more patients with MS and fatigue.

• Authors: Antonio Siniscalchi, Luca Gallelli, Grazia Angela Tolotta, Daniela Loiacono, Giovambattista De Sarro
• Journal: Clinical therapeutics (Clin Ther) Vol. 32 Issue 12 Pg. 2030-4 (Nov 2010) ISSN: 1879-114X [Electronic] United States
• PMID: 21118738 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antidepressive Agents, Second-Generation
• Bupropion

Topics

• Antidepressive Agents, Second-Generation (administration & dosage, therapeutic use)
• Bupropion (administration & dosage, therapeutic use)
• Fatigue (drug therapy)
• Female
• Humans
• Middle Aged
• Multiple Sclerosis, Relapsing-Remitting (drug therapy, physiopathology)
• Off-Label Use